# A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

> **NCT06799533** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 11 (actual)

## Conditions studied

- Malignant Melanoma
- Melanoma
- Metastatic Melanoma
- Solid Tumors

## Interventions

- **DRUG:** PF-08046031

## Key facts

- **NCT ID:** NCT06799533
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2025-05-01
- **Primary completion:** 2026-02-23
- **Final completion:** 2026-02-23
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.
- **Last updated:** 2026-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06799533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06799533, "A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06799533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*